Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | P-BCMA-101 CAR-T cells |
| Synonyms | |
| Therapy Description |
P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| P-BCMA-101 CAR-T cells | TNFRSF17 Immune Cell Therapy 27 | P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03288493 | Phase I | P-BCMA-101 CAR-T cells | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | Terminated | USA | 0 |